Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
Apr 26, 2023Apotex Corp. has expanded its oncology product portfolio with the launch of Bendamustine hydrochloride injection in the United States.
Bendamustine hydrochloride injection is an alkylating drug approved by FDA for treatment of patients with Chronic lymphocytic leukemia (CLL) and Indolent B-cell non-Hodgkin lymphoma (NHL). Please refer to the Prescribing Information for complete detail on indication, warnings and precautions.
Apotex’s Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL), New Drug Application No. 215033 contains the active drug ingredient (bendamustine hydrochloride) and is available in a multiple dose vial, ready-to-dilute solution, administered intravenously over 30 minutes for patients with CLL or 60 minutes for patients with NHL.
"We’re excited to launch this injection product, which provides an affordable, high-quality option for Americans undergoing cancer treatment," said Peter Hardwick, President, Apotex Corp.
About Apotex Corp.
Apotex Corp. is a US based company, headquartered in Weston, Florida. It and its global affiliates are leaders in generic pharmaceuticals and biosimilars and are committed to supplying patients with a broad portfolio of high-quality, affordable medicines covering all major therapeutic areas.
-30-
All media enquiries :
Jordan Berman
Vice-President, Global Corporate Affairs
[email protected]
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Aug 12, 2026
Apotex Announces First Quarter 2027 Results
TORONTO, ON, August 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada's largest pharmaceutical company, today announced its financial and operating results for the three months ended June 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Jul 17, 2026
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
Toronto, ON, July 16, 2026. Apotex Health Corp ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.
-
Jul 8, 2026
Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.